Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Specifically the study, published by Horizon Discovery co-founder Professor Alberto Bardelli (Universityof Torino) and SAB member Professor Sabine Tejpar (University of Leuven), found that patients carrying a particular and relatively common (20% of mutant KRAS cases) form of mutant KRAS (the G13D variant) are not resistant to Erbitux therapy, as was previously assumed. These findings, confirmed in the in-vivo and clinical patient samples, suggest that more detailed analysis of specific mutant KRAS variants in prospective clinical trials are required to reveal the true impact of specific mutant KRAS variants on patients receiving Erbitux therapy.
A copy of the publication is available to view online.
A copy of the publication is available to view online.
